Experimental Alzheimer's drug aims to quiet Brain's toxic tau

NCT ID NCT06372821

Recruiting now Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a drug called NIO752, given via spinal injection, to see if it can reduce production of tau protein in the brain. Tau buildup is linked to Alzheimer's damage. Ten people with mild to moderate Alzheimer's will receive either NIO752 or a placebo, and researchers will measure tau levels using a special labeling technique. The goal is to see if the drug safely lowers tau production.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NIO752 (antisense oligonucleotide)
What this could lead to: If it works, this could point toward a treatment that slows or stops Alzheimer's by reducing harmful tau buildup in the brain.
What could go wrong: This is a very early Phase 1 trial with only 10 participants, so it is too soon to know if the drug is safe or effective. The approach is experimental and may not work in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Alzheimer disease 3 Alzheimer disease 4 early-onset autosomal dominant Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF AMYLOID PRECURSOR PROTEIN (DISORDER) AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 1 (DISORDER) AUTOSOMAL DOMINANT ALZHEIMER DISEASE DUE TO MUTATION OF PRESENILIN 2 (DISORDER)

Contacts and locations

Locations

University College London Hospitals NHS Foundation Trust
RECRUITING

London, NW1 2PG, United Kingdom
Washington University in St. Louis
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.